Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
These tips reinforce discipline, such as setting clear categories, automating transfers, and reviewing results monthly.
17,300 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Strive raises the dividend on SATA preferred stock to 12.75% and deploys $50 million into Strategy's STRC, while incr...
Income-focused ETFs can deliver higher yields, but they often cap upside and introduce new risks. This guide breaks d...
Ulta Beauty shares have tumbled in the wake of earnings, but analysts see a potential entry point. The ulta beauty pr...
Autumn Durald Arkapaw became the first Black woman to win Best Cinematography at the 98th Academy Awards for Sinners,...
General Mills faces a turning point in 2026. This in-depth look examines earnings drivers, margins, and cash returns,...
The Midwest multifamily investment sector heating is gaining momentum as rates stabilize and rental demand strengthen...
February can be a turning point for rental property finances. This guide lays out seven concrete moves landlords can ...
Figuring out what considered good stock dividends means looking beyond yield. This article breaks down the metrics th...
IVV and SPY both track the S&P 500, but they aren’t identical. This guide breaks down cost, liquidity, tax considerat...
Apple abandons the stalemate of building bigger AI models. In a bold pivot, the company opens iOS 27 to rival assista...
Scotiabank boosted Cameco's price target to $175 as a global push for nuclear power gains traction and a new supply d...